ELVN
NASDAQEnliven Therapeutics Inc.
Price$37.00+0.08 (+0.22%)
01:30 PM07:45 PM
News · 26 weeks58-25%
2025-12-142026-06-07
Mix1790d
- SEC Filings6(35%)
- Insider5(29%)
- Other3(18%)
- Analyst2(12%)
- Earnings1(6%)
Latest news
25 items- INSIDERDirector Kunkel Lori Anne sold $345,351 worth of shares (10,000 units at $34.54) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 51,884 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- ANALYSTStifel initiated coverage on Enliven Therapeutics with a new price targetStifel initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $60.00
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- PREnliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 CongressEnliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will host a webcast conference call on Thursday, June 11, 2026 at 8:30 a.m. ET to discuss updated data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML) that will be presented at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden, and vi
- PREnliven Therapeutics to Present at Upcoming Investor ConferencesBOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences:TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m. ETJefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Thursday, June 4Time: 11:40 a.m. ETThe fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherape
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise sold $198,971 worth of shares (5,000 units at $39.79) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- PREnliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CMLAbstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohortIn patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeksELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients and longer treatment durationBOULDER, Colo., May 12, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the dis
- ANALYSTGuggenheim initiated coverage on Enliven Therapeutics with a new price targetGuggenheim initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $80.00
- SECSEC Form 10-Q filed by Enliven Therapeutics Inc.10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECEnliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdatePhase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the first quarter ended March 31, 2026, and provided a business update."Recent strategic momentum in CML validates a remaining un
- SECSEC Form DEFA14A filed by Enliven Therapeutics Inc.DEFA14A - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECSEC Form DEF 14A filed by Enliven Therapeutics Inc.DEF 14A - Enliven Therapeutics, Inc. (0001672619) (Filer)
- INSIDERSEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECSEC Form PRE 14A filed by Enliven Therapeutics Inc.PRE 14A - Enliven Therapeutics, Inc. (0001672619) (Filer)
- INSIDERSEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Enliven Therapeutics Inc.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECSEC Form S-8 filed by Enliven Therapeutics Inc.S-8 - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECSEC Form 10-K filed by Enliven Therapeutics Inc.10-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECEnliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateReported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e
- PREnliven Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceBOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. ET.The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.About Enliven TherapeuticsEnliven is a clinic
- INSIDERDirector Heyman Richard A. sold $32,196 worth of shares (1,230 units at $26.18) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
ELVN FAQ
6 questionsWhere does ELVN stock trade?
Enliven Therapeutics Inc. (ELVN) is listed on NASDAQ.What sector and industry is ELVN in?
Enliven Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enliven Therapeutics Inc. go public?
Enliven Therapeutics Inc. (ELVN) completed its IPO in 2020.What are analysts saying about ELVN?
Enliven Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy on 2026-06-09. Recent price targets range from $2700.00 to $4200.00.What companies are similar to ELVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ELVN side-by-side with any of them on Quantisnow.How can I track ELVN on Quantisnow?
Quantisnow aggregates Enliven Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELVN to receive live email and push alerts on every new disclosure.